NICE guidance framework: Relevant NICE recommendations include: CG189 (Obesity: identification, assessment and management) includes bariatric surgery indications and follow-up principles NG28 (Type 2 diabetes in adults) supports GLP-1 agonist use for glycaemic control and weight management in suitable patients with diabetes TA875 (Semaglutide for managing weight) recommends semaglutide 2.4mg (Wegovy) for adults with at least one weight-related condition and a BMI of at least 35 kg/m (or 30 kg/m for certain ethnic groups), within specialist weight management services [2] Post-bariatric medication principles: NHS bariatric services typically follow these principles when considering additional medications: Timing generally not initiated until weight stabilisation occurs, which varies between centres Indication clear clinical need, such as significant weight regain, inadequate initial weight loss, or persistent comorbidities Multidisciplinary assessment review by bariatric team including surgeon, physician, dietitian, and psychologist Nutritional optimisation ensuring adequate vitamin and mineral status before initiating appetite-suppressing medications Monitoring protocols regular follow-up for efficacy, adverse effects, and nutritional parameters Prescribing considerations: Ozempic is currently licensed for type 2 diabetes , not obesity alone
CJC-1295 Without DAC and the Dual Receptor Research Model CJC-1295 Without DAC engages the GHRH receptor pathway activating cAMP/PKA-mediated GH gene transcription and vesicle exocytosis while having no cross-reactivity with the GHS-R1a ghrelin receptor
The exact combination has not been tested in humans, so the combined picture is built by adding each compound's known signals together
MCAS, or mast cell activation syndrome, is a condition where your mast cells overreact, causing symptoms like food reactions, brain fog, skin flushing, fatigue, digestive issues, and anxiety
Accessed August 25, 2023, Revolo Biotherapeutics
